Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of Olanzapine (LY170053) in the Long-term Treatment for Patients With Bipolar I Disorder, Depressed

NCT00618748 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00618748
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00618748 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of Olanzapine (LY170053) in the Long-term Treatment for Patients With Bipolar I Disorder, Depressed
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
February 29, 2008
Completion date
September 30, 2010
Enrollment
101 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

bipolar i disorder